1.	Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000065713, E-E1295, CLB-9770, SWOG-E1295, NCI-P97-0081, NCT00003057
2.	Phase III Double Blind, Placebo Controlled Study of Sucralfate for Treatment-Induced Diarrhea in Patients Receiving Pelvic Radiation Therapy Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-949252, NCI-P97-0083
3.	Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000065974, NCCTG-969256, NCI-P97-0127, NCT00003170
4.	Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy Phase: Phase III Type: Supportive care Status: Completed Age: Any age Sponsor: NCI, Other Protocol IDs: CDR0000066979, RTOG-9809, RTOG-DEV-1016, NCT00003825
5.	Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000069304, NCCTG-N00CA, NCI-P02-0221, N00CA, NCT00033605
6.	Phase III Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effectiveness of Olsalazine in the Prevention of Acute Treatment-Induced Diarrhea in Patients Receiving Pelvic Radiotherapy (Summary Last Modified 04/93) Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-919253, NCI-P93-0038
7.	Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy Phase: Phase II Type: Supportive care Status: Completed Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: J0326, CDR0000441133, P30CA006973, JHOC-J0326, JHOC-03070804, J0326, NCT00258180
8.	Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan Phase: Phase II Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: MDA-2008-0005, CDR0000612205, 2008-0005, NCT00748215
9.	Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer Phase: Phase I Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: RP 02-24, RPCI-RP-0224, NCT00084721
10.	N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma Phase: Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Completed Age: 1 to 30 at diagnosis Sponsor: NCI, Other Protocol IDs: CDR0000373759, P01CA081403, N2003-01, NANT-2003-01, NCT00093353
11.	Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors Phase: Phase I Type: Supportive care, Treatment Status: Completed Age: Under 21 Sponsor: NCI, Other Protocol IDs: CPTCEF, NCT00143533
12.	Study of the Efficacy of Octreotide for the Treatment of Immunotherapy-Induced Diarrhea (Summary Last Modified 01/92) Phase: No phase specified Type: Supportive care Status: Completed Age: over 18 Sponsor: NCI Protocol IDs: NCI-92-C-0040, NCI-T91-0270N, T91-0270
13.	Study of Octreotide for Irinotecan-Induced Diarrhea in Patients With Metastatic Colorectal Cancer Phase: No phase specified Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: NU-00I1, NU-IRB-119-280, NOVARTIS-NU-00I1